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Thesensitivityofdiﬀerentrenalregions toxenobiotics requiresthedevelopment ofamultipleximmunoassayforthesimultaneous
analysis of kidney biomarkers. Calbindin D28K is a distal tubule-speciﬁc protein that can be detected in urine under pathological
conditions. In this study, a pair of anti-calbindin D28K antibodies was used in an immunoassay for the detection of calbindin
D28K expression in rat and human kidney and urine. Comparative analysis of the immunoassay was performed on the Meso
Scale Development (MSD) and Luminex platforms. Analysis on both platforms detected calbindin D28K concentrations between
100ng/mL and 100pg/mL. Luminex detected 10-fold the amount of calbindin D28K in samples analyzed as compared to MSD,
whereas calbindin D28K level in rat and human urine was below detection limit in both platforms. The application of the
immunoassaysdescribedhereinmaybeusefulintoxicologicalandpathologicalstudiesofdistaltubulardamageinratsandhuman.
Copyright © 2009 Samer Sourial et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The high renal blood ﬂow, renal biotransformation of
chemicals to reactive metabolites, and the nephrons ability
to concentrate tubular ﬂuid render the kidney sensitive
to xenobiotics. Due to the kidneys regional sensitivity to
xenobiotics, it is important to colocalize sites of biomarkers
release with pathological lesions [1].
Calbindin D28K is an intracellular, vitamin D-depend-
ent, calcium-binding protein that is expressed in the epithe-
lial cells of renal distal tubules [2, 3]. Previous studies
have demonstrated the inhibitory eﬀect of nephro-toxicants
such as Cyclosporin A on the expression of calbindin
D28K in distal tubules [4]. Furthermore, urinary analysis
of patients treated with Cisplatin as well as patients treated
by extracorporeal shock wave lithotripsy has indicated that
the expression of calbindin D28K can be increased under
pathological conditions [5, 6]. The speciﬁc localization of
calbindin D28K in distal tubules along with its pathophys-
iological release in urine makes this protein a potential
biomarker for distal tubule damage.
T h e r ei sa ne m e r g i n gt r e n di np h a r m a c e u t i c a li n d u s t r y
to evaluate biomarkers to determine the safety of drugs early
in clinical development. These biomarkers should predict
speciﬁc damage before functional loss. Limited sample
volume and excess costs have led to the development of
multiplex immunoassays for the simultaneous analysis of
multiple biomarkers.
The aim of this study was to compare an immunoassay
for calbindin D28K analysis on two multiplex platforms.
The same antibody pair was used for the single-plex analysis
of calbindin D28K in Luminex as compared to Meso Scale
Development (MSD). Analyses were performed using rat
recombinant calbindin D28K protein as a standard. Kidney
homogenates were used for validating the immunoassay on
both platforms. Results from this work may provide clues to
the further development of a multiplex immunoassay for the
simultaneous analysis of multiple kidney biomarkers.
2.MaterialsandMethods
2.1. Sample Preparation. Rat and human homogenates were
kindly provided by AstraZeneca (UK) and Cardiﬀ univer-
sity (UK), respectively. Brieﬂy, frozen tissue samples were
chopped into small cubes (approximately 1×1×1mm) and
homogenizedinRIPAbuﬀer(NewEngland Biolabs,Hitchin,
UK) containing Halt protease inhibitors (Pierce, Rockford,2 Journal of Biomedicine and Biotechnology
ILL,USA)usingaPolytron(Kinematica,Bohemia,NY,USA)
homogenizer. Samples were homogenized for two bursts of
30 seconds and placed on ice for one minute in between
bursts. Samples were then centrifuged at 10000 × gf o r5
minutes to remove insoluble debris. Frozen urine samples
from healthty rats and human individuals were used in this
study.
2.2. MSD Immunoassay. Anti-mouse immunoglobulin
plates (MSD, Gaithersburg, Md, USA) were used to
immobilize anti-calbindin D28K monoclonal antibody from
murine ascetic ﬂuid (Sigma, Saint Louis, Mo, USA). The
monoclonal antibody was diluted in Tris-Base Saline (TBS)
buﬀer to 5µg/mL and 25µL was added per well. The plate
was incubated overnight at 4◦Ca n de a c hw e l lw a sb l o c k e d
with 25µL of 5% Blocker-A (MSD) in TBS. After one hour
of incubation in blocking buﬀer, the plate was washed three
times with 0.1% Tween-containing TBS (wash-buﬀer). All
incubations in the MSD immunoassay were done on an
orbital shaker at 650rpm. Rat recombinant calbindin D28K
(Swant, Bellinzona, Switzerland) was used as a standard and
a dilution series was prepared in dilution buﬀer, starting
at 500ng/mL. Throughout the MSD immunoassay a buﬀer
containing 2.5% Blocker-A dissolved in TBS was used as a
dilution buﬀer. Duplicates of both standard and samples
were analyzed and 25µL were pipetted per well. After one
hour of incubation, the plate was washed three times with
wash-buﬀer and 25µL of anti-calbindin D28K polyclonal
rabbit antibody (Sigma, Saint Louis, Mo, USA) was added
per well. The polyclonal antibody was diluted to 2µg/mL in
dilution buﬀer and 25µL was added per well. After one hour
ofincubation,platewaswashedthreetimeswithwash-buﬀer
and 25µL of sulfo-tagged goat anti-rabbit antibody (MSD),
2µg/mL, was added per well. The plate was then covered
from light while incubating for 30 minutes and then washed
three times with wash-buﬀer. Finally, 150µLo f2 xM S Dr e a d
buﬀer T was added per well and the plate was measured on
the MSD Sector Imager 6000. The raw data was analyzed
using the default setting of the Discovery Workbench 3.0
software (MSD).
2.3. Luminex Immunoassay. Anti-mouse IgG1 beads
(Upstate, Temecula, Calif, USA) were used to capture anti-
calbindin D28K murine antibody. The beads were vortexed
vigorously for one minute and diluted 1 : 40 in TBS. The
plate was pre-wet with 150µL TBS for 10 minutes and
then aspirated using a vacuum manifold with the bottom
of the plate blotted on paper towel to remove excess ﬂuid.
Throughout the assay the beads were kept protected from
light and the incubations were performed on an orbital
shaker at 650rpm. The diluted beads were vortexed for one
minute and 25µL was added per well followed by 25µLo f
anti-calbindin D28K murine antibody diluted in TBS to a
concentration of 5µg/mL. After incubating for one hour, the
ﬂuid was removed using a vacuum manifold and the wells
were washed twice with 0.1% Tween-containing TBS wash-
buﬀer. As with the MSD immunoassay, the dilution series of
recombinant calbindin D28K was used as a standard. TBS
containing 0.05% bovine serum antigen (BSA) was used as
dilution buﬀer. Duplicates of both standard and samples
were analyzed and 50µL were pipetted per well. After one
hour of incubation, the plate was washed twice with wash-
buﬀer and 50µL of anti-calbindin D28K polyclonal rabbit
antibody, 2µg / m L ,w a sa d d e dp e rw e l l .A f t e ro n eh o u ro f
incubation, the plate was washed twice with wash-buﬀer and
50µL R-Phycoerythrin- (RPE-) conjugated goat anti-rabbit
antibody (Pierce), 1.25µg/mL, was added per well. The
plate was then incubated 30 minutes and washed twice
with wash-buﬀer. Finally 150µL of sheath buﬀer (Bio-Rad,
Hercules, Calif, USA) was added to each well and incubated
for 10 minutes. The plate was measured on the Luminex100
(Luminex Corporation, Austin, Tex, USA) and analyzed
using Bio-Plex Manager 3.0 (Bio-Rad). The analysis software
was set to acquire data using 100µLo fs a m p l ep e rw e l l
and to collect a total of 100 beads. The standard curve was
calculated using a 5-parameter logistic ﬁt curve generated
from 7 standards.
3. Results and Discussion
The need for multiple biomarker analysis in limited sample
volumes as well as the demand of decreasing costs has led
to the development of multiplex immunoassay techniques.
Several studies have previously compared the analysis of
diﬀerent biomarkers on diﬀerent commercially available
multiplex platforms [7–11]. Using the same antibody pair, in
thisstudywecomparedtheanalysisofadistaltubule-speciﬁc
protein on the MSD and Luminex platforms.
Recombinant calbindin D28K was used as a standard
and was diluted to produce 8- versus 7-standard concentra-
tions for the MSD and Luminex immunoassay, respectively.
Figure 1 depicts the standard curves for both MSD and
Lumniex measurement of calbindin D28K. The software
used in MSD analysis regarded the lowest concentration
(25pg/mL) on standard curve to be below detection range.
The signal coeﬃcient of variation (cv) was less than 10%
for both platforms, while the calculated concentration cv
was high for the lower concentrations on the standard
curves.MSDdisplayedawiderdynamicrangethanLuminex,
detecting concentrations at a maximum of 500ng/mL and a
minimumof50pg/mL.Thehighcalculatedconcentrationcv
at50pg/mL,setcalbindinD28Klowerlimitofdetection(lld)
to 100pg/mL on the Luminex platform.
The earliest report on a calbindin D28K immunoassay,
made use of anti-calbindin D28K-coupled Sepharose beads
and the standard used was native calbindin D28K puriﬁed
from human kidney tissue [12]. Similar to the Luminex
assay, this assay had a lld equivalent to 100pg/mL. While
the earlier-described immunoassay detected calbindin D28K
in healthy individuals [5], urinary analysis of both normal
rats and human indicated that the calbindin D28K level was
below the detection limit in both the MSD and Luminex
immunoassay (data not shown). Furthermore, it was not
possible to accurately measure urinary spiked recombinant
calbindin D28K, due to the recombinant protein instability
in urine.Journal of Biomedicine and Biotechnology 3
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Figure 1: (a) Calbindin D28K standard curve analysis on MSD. (b) Luminex analysis of calbindin D28K; with standard curve indicating the
ﬂuorescence intensity (FI) at the diﬀerent concentrations.
Table 1: Linearity analysis of rat cortical kidney homgenate dilutions.
MSD Luminex
Dilution factor Measured pg/mL CV%+ %Mean
∗ Measured pg/mL CV%+ %Mean
∗
100 5554 1.2 131 49762 0.1 128
200 2410 1.9 114 22802 5.1 117
400 1233 11 116 11568 1.2 119
800 424 12 80 5421 8.0 112
1600 247 6.7 93 2709 5.2 111
3200 110 16 83 1120 3.7 92
6400 55 14 83 422 12 69
12800 — 155 6.2 51
∗Calculated concentration (dilution factor × measured concentration) as a percentage of the average of the calculated concentration from all dilutions. The
average calculated concentration of rat cortical kidney homogenate analyzed by MSD and Luminex was 424ng/mL and 3.9µg/mL, respectively.
+Coeﬃcient of variation.4 Journal of Biomedicine and Biotechnology
Table 2: Precision analysis using rat cortical kidney homogenate.
MSD Luminex
Dilution 1 : 400 1 : 4000 1 : 400 1 : 4000
Mean 945 87 14167 1041
SD
∗ 97 17 723 103
CV
+ 10% 20% 5% 10%
∗Standard of deviation.
+Coeﬃcient of variation.
Table 3: Interassay variation analysis of rat cortical kidney
homogenate.
Assay MSD (ng/mL) Luminex (µg/mL)
1 424 3.9
2 407 3.1
3 283 3.3
SD
∗ 76 0.4
∗Standard of deviation.
Table 4: MSD speciﬁcity analysis of human kidney homogenate.
Region Concentration (ng/mL)
Cortex 64
Medulla 3
Papilla —
In an attempt to assess the immunoassays ability in
measuring native calbindin D28K, kidney homogenates were
analyzed. Since calbindin D28K is expressed in distal tubuli,
rat cortical kidney homogenate was used in validating
the immunoassays sensitivity and linearity. Whereas MSD
had a higher sensitivity for recombinant calbindin D28K,
Luminex detected calbindin D28K in kidney homogenate
at the highest dilution factor tested (Table 1). To assess
the immunoassays linearity, the calculated concentration
(dilution factor ×measured concentration) was expressed as
a percentage of the average of the calculated concentration
from all dilutions. There was no clear diﬀerence in linearity
between Luminex and MSD measurement, except at the high
kidney homogenate dilutions where lower level of calbindin
D28K was measured by the Luminex assay. Furthermore,
Luminex detected almost 10-fold the amount of calbindin
D28K as compared to MSD. Previous studies comparing
diﬀerent multiplex platforms have also reported quantitive
diﬀerences in the analysis of diﬀerent proteins [7, 8]. The
diﬀerence in detected amounts of calbindin D28K could
be due to technical diﬀerences between the two platforms.
Immobilization of capture antibodies on beads in Luminex
may provide a larger total surface than immobilization of
capture antibodies at the bottom of the wells in MSD plates.
This in turn may allow for higher accessibility for the capture
antibody to interact with calbindin D28K in solution, and
subsequently a higher detection.
To investigate the immunoassays measurement of high
versus low concentrations of calbindin D28K, two diﬀerent
dilutions of rat cortical kidney homogenate were analyzed.
Precision analysis of the two diﬀerent platforms indicated
that Luminex had lower cv values as compared to MSD,
at both high and low concentrations of calbindin D28K
(Table 2).Toassesstheinterassayvariationinbothplatforms,
the average of the calculated calbindin D28K concentra-
tion (dilution factor × measured concentration) of all the
diﬀerent kidney homogenate dilutions from three diﬀerent
experiments was compared. Despite the higher standard of
deviation (SD) value, Luminex displayed a lower interassay
variation as compared to MSD (Table 3).
WhereastherecombinantcalbindinD28Kisclonedfrom
rat and the analyses presented so far was with rat kidney
homogenate, the antibodies used in this immunoassay cross-
reacts with human calbind D28K. To test the speciﬁcty of
the immunoassay, homogenates from diﬀerent regions of
the human kidney were analyzed with MSD. The result
demonstrated the immunoassays specifcity to the predomi-
nant expression of the distal tubule calbindin D28K in the
cortical region (Table 4).
4. Conclusions
The methods described herein will enable future multiplex
analysis of calbindin D28K in combination with other
kidney-damage biomarkers, which may then be used in
investigating distal tubule damage in rat and human toxico-
logical studies. Whereas MSD had a wider dynamic range,
analysis of calbindin D28K indicated that Luminex has
highersensitivityandprecision.Theselectionoftheplatform
most suitable for kidney biomarker analysis will depend on
the other analytes available and other practical factors such
as cost and ease of analysis.
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